Clinical trial
Response Features, Efficacy and Safety of CD318-targeted CAR-T Cell Therapy Against Pancreatic Cancer - ResCPa Study
NCT07153289 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Response Features, Efficacy and Safety of CD318-targeted CAR-T Cell Therapy Against Pancreatic Cancer - ResCPa Study
- Lead sponsor
- University Hospital Tuebingen
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- July 31, 2026
- Completion date
- December 31, 2028
- Enrollment
- 38 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.